Aperio Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Aperio Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$91K	Sell	18,924 -32,087	-63%	-$162K	﹤0.01%	2384
2020 Q3	$297K	Buy	51,011 +32,241	+172%	+$193K	﹤0.01%	2073
2020 Q2	$127K	Buy	18,770 +1,521	+9%	+$11.5K	﹤0.01%	2254
2020 Q1	$110K	Buy	+17,249	New	+$138K	﹤0.01%	2209
2019 Q3	–	Sell	-3,235	Closed	-$48K	–	2884
2019 Q2	$48K	Buy	+3,235	New	+$58.5K	﹤0.01%	2544
2018 Q2	–	Sell	-5,060	Closed	-$267K	–	2292
2018 Q1	$267K	Sell	5,060 -13	-0.3%	-$759	﹤0.01%	2012
2017 Q4	$345K	Sell	5,073 -188	-4%	-$13.1K	﹤0.01%	1875
2017 Q3	$434K	Buy	5,261 +168	+3%	+$13.3K	﹤0.01%	1728
2017 Q2	$477K	Buy	5,093 +83	+2%	+$5.08K	﹤0.01%	1682
2017 Q1	$319K	Buy	+5,010	New	+$305K	﹤0.01%	1794
2015 Q4	–	Sell	-3,127	Closed	-$288K	–	2030
2015 Q3	$288K	Buy	3,127 +276	+10%	+$23.9K	﹤0.01%	1582
2015 Q2	$251K	Sell	2,851 -61	-2%	-$5.22K	﹤0.01%	1740
2015 Q1	$216K	Buy	+2,912	New	+$206K	﹤0.01%	1786

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aperio Group's CLVS Position: Q4 2020 in Review

Aperio Group reduced its Clovis Oncology, Inc. (CLVS) stake by 63% in Q4 2020, selling an estimated $162K and leaving 18,924 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Aperio Group first reported a position in CLVS in Q1 2015 and has held it in 13 quarters since. The position peaked at $477K in Q2 2017. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

Aperio Group held 18,924 shares of Clovis Oncology, Inc. worth $91K as of Q4 2020.
Aperio Group sold 32,087 Clovis Oncology, Inc. shares in Q4 2020, an estimated $162K.
Clovis Oncology, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2384 holding.
Aperio Group first reported a position in Clovis Oncology, Inc. in Q1 2015 and has held it in 13 quarters since.
Aperio Group's Clovis Oncology, Inc. position peaked at $477K in Q2 2017.
159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.